Xencor (XNCR) EBT (2013 - 2026)
Xencor (XNCR) posted quarterly EBT of -$128.6 million for Q1 2026, down 166.52% year-over-year from $193.4 million in Q1 2025, and down 2915.38% quarter-over-quarter from -$4.3 million in Q4 2025.
Xencor (XNCR) EBT (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported EBT for 14 consecutive years, with -$128.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT fell 166.52% year-over-year to -$128.6 million; the TTM figure through Mar 2026 stood at -$170.0 million (up 18.69% YoY), while the FY2025 annual figure was -$89.6 million, up 61.85% from the prior year.
- EBT retreated to -$128.6 million in Q1 2026 per XNCR's latest filing, from -$4.3 million in the prior quarter.
- Across five years, EBT topped out at $25.8 million in Q1 2022 and bottomed at -$128.6 million in Q1 2026.
- Historically, EBT has averaged -$41.1 million across 5 years, with a median of -$44.6 million in 2024.
- Annual changes were most pronounced in 2022 — EBT jumped 259.43% — and 2023, when it slumped 327.17%.
- Xencor's EBT stood at -$12.5 million in 2022, then retreated by 1.53% to -$12.6 million in 2023, then plunged by 252.49% to -$44.6 million in 2024, then soared by 90.43% to -$4.3 million in 2025, then slumped by 2915.38% to -$128.6 million in 2026.
- Business Quant data shows XNCR's EBT at -$128.6 million in Q1 2026, -$4.3 million in Q4 2025, and -$6.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Xencor | 1.73 Bn | 1.36 Bn | - | -21.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -21.92 Mn |
| Mar 31, 2026 | -128.64 Mn |
| Dec 31, 2025 | -4.27 Mn |
| Sep 30, 2025 | -6.03 Mn |
| Jun 30, 2025 | -31.08 Mn |
| Mar 31, 2025 | -48.27 Mn |
| Dec 31, 2024 | -44.58 Mn |
| Sep 30, 2024 | -47.44 Mn |
| Jun 30, 2024 | -68.78 Mn |
| Mar 31, 2024 | -74.12 Mn |
| Dec 31, 2023 | -12.65 Mn |
| Sep 30, 2023 | -24.27 Mn |
| Jun 30, 2023 | -71.11 Mn |
| Mar 31, 2023 | -58.57 Mn |
| Dec 31, 2022 | -12.46 Mn |
| Sep 30, 2022 | -31.67 Mn |
| Jun 30, 2022 | -60.59 Mn |
| Mar 31, 2022 | 25.78 Mn |
| Dec 31, 2021 | 73.06 Mn |
| Sep 30, 2021 | -40.19 Mn |